EyeFocus Eye Care Innovation Conference

31 January 2017, London, UK.
EyeFocus is holding a one day conference about eye-care innovation to end the second EyeFocus program. The conference is instead of the traditional demo day, and will go beyond startups pitching to investors, instead presenting the ecosystem EyeFocus has built in eye-care innovation.

The conference will bring together thought leaders from across eye-care, innovation, and tech. The day will feature keynote talks, discussion panels, and short pitches from a broad range of the companies in the EyeFocus program, from startups to developed businesses.

The aim of the day is to share the built ecosystem, and the knowledge clustered around EyeFocus, and to promote innovation in eye-care. The day will be a mix of networking, education, and information for people working in eye-care, health tech, and startups.

EyeFocus Eye Care Innovation Conference is sponsored by Bayer, and has partnered with the world famous Royal National Institute for Blind People (RNIB), and Royal Academy of Engineering (RAENG) to bring thought leaders from across the eye-care spectrum together for a unique event in the centre of London.

For further information and to buy tickets, please visit:
https://www.eventbrite.com/e/eyefocus-conference-tickets-29612858858?aff=eHealthNews&afu=197085922377

About EyeFocus
EyeFocus is the world's first eye-care accelerator and innovation program. We run events around the world to bring together opinion leaders and practitioners in eye-care innovation to leave our ecosystem better connected, and to focus academics, innovators, and practitioners on thinking about how to create new products and solutions for people who are blind or visually impaired.

EyeFocus is a project of Newsquare Innovation. Newsquare develops programs to create connected ecosystems in healthcare innovation, accelerating early stage companies, and building bridges between academia, industry, entrepreneurs, and healthcare.

Most Popular Now

New analysis shows Novartis Entresto improves glyc…

Novartis has announced results of a new post-hoc analysis in a subgroup of patients with reduced ejection fraction heart failure (HFrEF) and diabetes suggesting that Entr...

Read more

Mutual Recognition promises new framework for phar…

The United States and the European Union (EU) completed an exchange of letters to amend the Pharmaceutical Annex to the 1998 U.S.-EU Mutual Recognition Agreement. Under t...

Read more

Potential drug candidates halt prostate and breast…

Scientists on the Florida campus of The Scripps Research Institute (TSRI) have designed two new drug candidates to target prostate and triple negative breast cancers. The...

Read more

Novartis' Cosentyx shows almost all psoriasis pati…

Novartis has announced a new analysis showing that moderate-to-severe psoriasis patients treated with Cosentyx® (secukinumab) rapidly regain clear or almost clear skin (P...

Read more

Scientists stimulate immune system, stop cancer gr…

Researchers at the University of Illinois at Chicago report that increasing expression of a chemical cytokine called LIGHT in mice with colon cancer activated the immune ...

Read more

Johnson & Johnson completes acquisition of Abb…

Johnson & Johnson (NYSE: JNJ) has completed the acquisition of Abbott Medical Optics (AMO), a wholly-owned subsidiary of Abbott. The all-cash $4.325 billion acquisition w...

Read more

New England Journal of Medicine publishes long-ter…

In 2001 the U.S. Food and Drug Administration granted priority review for imatinib mesylate, sold under the name Gleevec®*, as an oral therapy for patients with chronic m...

Read more

Bristol-Myers Squibb expands focus on precision me…

Bristol-Myers Squibb Company (NYSE: BMY) announced its equity investment and plans for a research collaboration with GRAIL Inc., a life sciences company whose mission is ...

Read more

Volkswagen's excess emissions will lead to 1,200 p…

In September 2015, the German Volkswagen Group, the world's largest car producer, admitted to having installed "defeat devices" in 11 million diesel cars sold worldwide b...

Read more

MedImmune and Sanofi Pasteur form alliance to deve…

MedImmune, the global biologics research and development arm of AstraZeneca, and Sanofi Pasteur, the vaccines division of Sanofi, have announced an agreement to develop a...

Read more

Cooking at home tonight? It's likely cheaper and h…

Researchers from the University of Washington School of Public Health have been peeking into kitchens - via interviews - for years now. They've just published results sho...

Read more

Human antibody for Zika virus promising for treatm…

Researchers have determined the structure of a human antibody bound to the Zika virus, revealing details about how the antibody interferes with the infection mechanism - ...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]